GLP-1 Revolution
by Amaltash Advisors LLC
$1,436
+14.47% past month
Nov 16, 2026
$1,431.67-0.82%
Eli Lilly closed down 0.82%, in line with comparable pharmaceutical companies, which fell 0.79% on average with all 6 of 6 lower . Seeking Alpha reported that Lilly agreed a deal worth up to $1.5B to acquire Calytrix Bio, tied to an upfront payment and clinical and regulatory milestones .
Nov 13, 2026
$1,443.5+1.14%
Nov 12, 2026
$1,427.28-0.70%
Lilly shares fell on a day when the company broke ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity medicines . Seeking Alpha reported, citing a report, that China approved Lilly's GLP-1 weight-loss pill . The Motley Fool noted that an experimental Lilly GLP-1 was effective in treating osteoarthritic knee pain . None of these items shows why the shares closed lower.
Nov 11, 2026
$1,437.29+0.35%
Seeking Alpha reported that Lilly was sued over the alleged firing of a sales rep for complaints about Mounjaro misbranding . The shares still closed slightly higher, and the items give no explanation for the gain.
Nov 10, 2026
$1,432.29+1.44%
Nov 9, 2026
$1,411.95+4.28%
Seeking Alpha reported that Eli Lilly released phase 3 data showing its oral GLP-1 Foundayo cut sleep apnea severity and aided weight loss . Seeking Alpha also reported that the FDA would require a rare vision loss warning on GLP-1 drugs including Zepbound . Comparable pharmaceutical companies rose 0.81% on average, with 5 of 6 higher, so the shares' gain was larger than the cohort's .
Nov 6, 2026
$1,354-0.79%
Lilly shares closed down 0.79%. Eli Lilly and Hims & Hers Health announced an agreement to expand access to Zepbound through the Hims & Hers platform . Seeking Alpha reported that Hims & Hers stock rose on the partnership . The items hold no sector or market figures, so the move cannot be compared with peers.
Closing prices for LLY. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.
As of Nov 16, 2026, Eli Lilly & Co. is 0.8% below its 52-week high. Its largest decline in the period shown was -34.8% (Aug 30, 2024 to Aug 8, 2025).
As of Nov 16, 2026, Eli Lilly & Co. closed 0.8% below its 52-week closing high, set on Nov 13, 2026.
Eli Lilly & Co. fell 34.8% from Aug 30, 2024 to Aug 8, 2025, close to close, the largest decline in daily data since Nov 18, 2021. It closed back above that high on Nov 10, 2025.
Learn how max drawdown is measured, and how past market drawdowns played out.
Daily closing prices from Nov 18, 2021 to Nov 16, 2026, adjusted for splits but not dividends. Past price movements do not predict future results.
How much would it be worth today? $1,000 invested in Eli Lilly & Co. (LLY) 10 years ago, at the Nov 30, 2016 close, would be worth about $21,330 today, based on the Nov 16, 2026 close — a gain of $20,330 (+2,033.0%), dividends not included. Along the way it fell as much as 34.8% from a high, between Aug 30, 2024 and Aug 8, 2025. Before Nov 2021 this uses monthly highs and lows.
Return calculator
Worth today, at the Nov 16, 2026 close
$111,635
+$98,735 · +765.4%The cash line is the same deposits earning nothing. A savings account would usually have paid some interest.
Past performance of LLY's closing prices (split-adjusted; dividends not included). It ignores fees, taxes and trading costs. The results change as prices update and with the amounts you enter. Past results do not predict future results, and a single stock can fall hard. We show this for every asset in our directory; it is not a recommendation to buy or sell LLY.
Try the full investment calculatorThe coffee test
A $5 coffee every workday comes to about $100 a month. Over 5 years that's 1,200 coffees, or $6,000.
The same $100 a month put into LLY since November 2021 would be worth $16,039 today.
That's 3,208 coffees. Make it a large.
Past performance, month-end prices. Not a forecast.
| Invested | Start date | LLY price then | $1,000 → | $10,000 → | Change |
|---|---|---|---|---|---|
| 1 year | Nov 28, 2025 | $1,075.47 | $1,331 | $13,312 | +33.1% |
| 3 years | Nov 30, 2023 | $591.04 | $2,422 | $24,223 | +142.2% |
| 5 years | Nov 30, 2021 | $248.04 | $5,772 | $57,719 | +477.2% |
| 10 years | Nov 30, 2016 | $67.12 | $21,330 | $213,300 | +2,033.0% |
$10,000 invested in Eli Lilly & Co. (LLY) at the Nov 30, 2016 close would have been worth about $213,300 at the Nov 16, 2026 close — a gain of $203,300 (+2,033.0%), dividends not included.
LLY closed at $67.12 on Nov 30, 2016 (split-adjusted). It closed at $1,431.67 on Nov 16, 2026.
Putting $100 into LLY at each month-end close from Nov 30, 2016 — 120 purchases, $12,000 in total — would have been worth about $92,438 at the Nov 16, 2026 close: a gain of $80,438 (+670.3%), dividends not included.
LLY closed at $1,431.67 on Nov 16, 2026. A year earlier it closed at $1,025.28 on Nov 14, 2025, so it is up 39.6% over that year. Five years earlier it closed at $254.76 on Oct 29, 2021 (up 462.0% since then). Its highest close in the year to Nov 16, 2026 was $1,443.50 on Nov 13, 2026, and its lowest was $851.21 on Apr 29, 2026. These are split-adjusted closing prices; dividends are not included.
LLY last closed at $1,431.67 on Nov 16, 2026. This page is updated once a day, so it does not show live prices.
Over one year, from $1,025.28 on Nov 14, 2025 to $1,431.67 on Nov 16, 2026, it was up 39.6%. Over five years, from $254.76 on Oct 29, 2021 to $1,431.67 on Nov 16, 2026, it was up 462.0%. These are split-adjusted closing prices; dividends are not included.
As of Nov 16, 2026, Eli Lilly & Co. had a market value (market cap) of about $1.3 trillion and a price-to-earnings (P/E) ratio of 38.9.
Eli Lilly makes and sells medicines for diabetes, weight loss, cancer and immune system problems. It also makes medicines for brain and nerve conditions.
We do not tell anyone whether to buy or sell LLY, and past results do not predict future results. Its largest fall from a high since Nov 18, 2021 was 34.8%, from $960.02 on Aug 30, 2024 to $625.65 on Aug 8, 2025. A single stock can lose much of its value, so think about how much you could afford to lose. Our investment calculator shows how past amounts would have changed.
Past performance of LLY's closing prices. Not a forecast. This is general information, not a recommendation to buy or sell LLY.
Try the full investment calculatorThese strategies on Amaltash hold LLY today. We show them so you can see where it is used. This is not a recommendation to invest in any of them.
by Amaltash Advisors LLC
by Amaltash Advisors LLC
This strategy bets on the booming weight-loss and metabolic health revolution — and it goes far beyond just the blockbuster drug makers you've heard about on the news. It builds a diversified basket across the entire ecosystem: companies developing next-generation obesity and diabetes treatments, the diagnostic labs helping doctors identify and monitor patients, the device makers tracking metabolic health, the clinics and care delivery platforms scaling treatment access, and even the insurers reshaping how metabolic disease is covered and reimbursed. The strategy focuses exclusively on companies that have already shown sustained upward price momentum over recent years — it's not trying to pick speculative moonshots, but rather ride names that the market has already started rewarding. The basket rotates and rebalances to keep exposure fresh, leaning into the strongest performers while trimming names that lose their footing. It's long-only and growth-oriented, meaning it profits when these companies rise in value — it does not short or hedge. The personality is opportunistic but not reckless: a built-in drawdown guardrail is designed to protect the portfolio if the sector hits a rough patch, targeting a maximum loss limit so a bad quarter doesn't wipe out a good year. Imagine this scenario: A major insurer announces it will cover GLP-1 treatments broadly. Drug makers surge, but so do the glucose monitors, the telehealth obesity clinics, and the cardiac device companies treating downstream complications. This strategy is already holding across all of those layers — capturing the wave rather than just one drop of it.
View strategy →